Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 393Terminated 122Recruiting 118Active not recruiting 84Unknown 37Not yet recruiting 22Withdrawn 18Suspended 3Temporarily not available 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Paclitaxel 5Gemcitabine 3Nivolumab 2Injections 2E 7107 2Docetaxel 2Carboplatin 2Antibodies, Monoclonal 2130-nm albumin-bound paclitaxel 2venetoclax 1trastuzumab biosimilar HLX02 1taxane 1spartalizumab 1resiniferatoxin 1poly(I).poly(c12,U) 1pegamotecan 1palbociclib 1lenvatinib 1imisopasem manganese 1icotinib 1gusacitinib 1famitinib 1eniluracil 1dabrafenib 1cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1cobimetinib 1brincidofovir 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1abivertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × INDUSTRY × Gemcitabine × Clear all
NCT03417921 2025-10-01

Pancreatic

Ability Pharmaceuticals SL

Phase 1/2 Suspended
60 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03002103 2023-04-26

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

SynCore Biotechnology Co., Ltd.

Phase 3 Suspended
420 enrolled
Breast

Triple Negative Breast Neoplasms

NCT00536770 2007-11-06

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

Novacea

Phase 2 Suspended
132 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡